

EIGHTH GLOBAL SUMMIT PRECISION DIAGNOSIS AND TREATMENT OF PROSTATE CANCER

SAVE THE DATE!

October 8-10, 2024

Creating the Future of Patient Care

Scientific Program Draft - April 9, 2024

(The Current Sessions and Presentations are in Eastern Standard Time and Subject to Change)

TUESDAY, OCTOBER 8, 2024

8-00AM	WELCOME	AND INTRODUCTION

Faina Shtern, MD, President and CEO, AdMeTech Foundation

8:15AM SESSION I (PART 1): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION

Moderators:

Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office, European Association of Urology

Sigrid Carlsson, MD, PhD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden

8:30AM Topic 1: State of the Art and Future Directions in "Smart" Prostate Cancer Screening

8:30AM Topic 1A: Year in Review: Emerging Data and Advances in Screening: Sigrid Carlsson, MD, PhD, MPH

8:40AM Q & A

8:42AM Topic 1B: Overview - Why We Need Organized Screening Programs; Hendrik Van Poppel, MD, European Association of Urology Policy Office Chairman, and Professor, Department of Urology, University Hospitals Leuven.

Belgium (TBC)

8:52AM Topic 1C: Update on PROBASE Trial: Baseline PSA in Young Men (Aged 45 and 50): Peter Albers, MD, Professor and Chairman, Department of Urology and Medical Director, Comprehensive Cancer Center, University Hospital, Heinrich-Heine-University, Düsseldorf; Professor of Urology and Division Head, Personalized Early Detection of Prostate Cancer, German Cancer Research Center, Heidelberg, Germany; and Chairman, Scientific Congress Office,

European Association of Urology

9:02AM Q & A 9:06AM Topic 1D: PROFILE Study - Early Data on Targeted Screening for Prostate Cancer in Men of African and African Caribbean Ancestry: Jana McHugh, MB, BCh, BAO, Clinical Research Fellow, Institute of Cancer Research and Honorary Senior Registrar in Clinical Oncology, Royal Marsden Hospital, NHS Foundation Trust, London, United Kingdom 9:16AM Q & A 9:18AM Topic 1E: Multi-Cancer Early Detection (MCED) 9:18AM Overview of MCED - Performance and Impact on Prostate Cancer: Erik A. Klein, MD, Distinguished Scientist, GRAIL; and Emeritus Andrew C. Novick Distinguished Professor and Chair, Glickman Urologic and Kidney Institute and Cleveland Clinic Lerner College of Medicine Q & A 9:28AM MRI-Based Prostate Cancer Screening in an Era of MCEDs: Mark Emberton, MD, Dean, Faculty of Medical Sciences, 9:30AM and Professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London; and Honorary Consultant Urologist, University College London Hospital, United Kingdom Q & A 9:40AM Topic 1F: Prostate Cancer Screening Practices in Europe: Monique Roobol, PhD, Professor of Decision Making in 9:42AM Urology and the Head of the Scientific Research Office, Department of Urology, Erasmus University Medical Centre, Cancer Institute, Rotterdam, The Netherlands Q & A 9:52AM Topic 1G: Update on IMPACT - Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers and 9:54AM Men with Lynch Syndrome: Ros Eeles, PhD, FRCP, FRCR, Professor of Oncogenetics, The Institute of Cancer Research, Royal Marsden Hospital, University of London; and Honorary Consultant in Cancer Genetics and Clinical Oncology, National Health Service (NHS) Foundation Trust, London, United Kingdom 10:04AM Q & A 10:06AM-Panel Discussion: "Smart" Prostate Cancer Screening 11:00AM **COFFEE BREAK** 11:00AM-11:30AM SESSION I (PART 2): PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING 11:30AM AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION Moderators: Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel (TBC) Clare M. C. Tempany-Afdhal, MB, BAO, BCh, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women's Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization (TBC) 11:30AM Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling Topic 2A: Current and Emerging Molecular and Genetic Diagnostics 11:30AM

11:30AM Overview of Liquid Biomarkers: E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal (TBC)

11:40AM Q & A

11:42AM- Panel Discussion: Molecular and Genetic Diagnostics 12:00PM

12:00PM Topic 2B: Current and Emerging Imaging Tools and Targeted Biopsies 12:00PM OPTIMUM Trial - A 3-Arm Randomized Controlled Clinical Study Evaluating the Role of Micro-Ultrasound in Men with Clinical Suspicion of Prostate Cancer: Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center, and Chair, World Urologic Oncology Federation PI-RADS. Sponsored by Exact Imaging. 12:12PM MRI Standardization and Clinical Evaluation: Clare Tempany, MB, BAO, BCh (TBC) Q & A 12:22PM 12:24PM Quality Improvement American College of Radiology Program in Prostate MRI: Andrei Purysko, MD, Associate Professor of Radiology, Cleveland Clinic Lerner College of Medicine. Section of Abdominal Imaging and Nuclear Radiology, Imaging Institute and Glickman Urological and Kidney Institute Cleveland Clinic (TBC) 12:34PM Q & A Multi-modality (MRI+PET) Imaging for Improved Detection of csPC: David Margel, MD, PhD, Founder, Rabin Medical 12:36PM Center and BRCA clinic, Member, Early Detection Committee at the Cancer War Society (TBC) 12:46PM Q & A 12:48PM Bi-Parametric Optimized 15 min Protocol for Prostate MRI - Are we there yet? Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School 1:58PM Q & A 2:00PM Optimizing MRI Targeted Biopsy - Including Endorectal Imaging for Tumor Localization and In-Bore Biopsy for Tissue Diagnosis: Fergus Coakley, MD, Professor and Chair of Diagnostic Radiology, School of Medicine, Oregon Health and Science University 1:10PM-Q & A 1:12PM Panel Discussion: Imaging Modalities and Targeted Biopsies 1:30PM-**LUNCH BREAK** 2:30PM 2:30PM Topic 3: NCCN Guidelines for Early Detection of Prostate Cancer 2024: Preston Sprenkle, MD (TBC) Q & A 2:40PM 2:42PM-General Discussion - Moderators, Speakers and Mark Katz, MD, Assistant Professor of Surgery, Boston University 3:00PM School of Medicine 3:00PM-**COFFEE BREAK** 4:00PM PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI-4:00PM MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT **Moderators:**

Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, **UCLA**

Michael H. Johnson, MD, Chief and Associate Professor of Urology, Washington University School of Medicine, and Program Director, Society of Urologic Oncology Fellowship

Amita Dave, PhD, Vice-Chair, Radiology-Medical Physics Outreach; Deputy Service Chief for Predictive Informatics, and Director of Quantitative Imaging, Department of Radiology, Memorial Sloan Kettering Cancer Center

3:30PM	Connected Care and Latest Developments in Prostate Cancer Management: Ilya Gipp, MD, PhD, Global Clinical Leader - Oncology, GE Healthcare
3:50PM- 5:30PM	Panel on Artificial Intelligence and Management of Big Data: Clinical Applications, Standardization, Fundamental Challenges and Future Vision (Participants to be announced)
3:50PM	Norwegian PSA Registry: Jan Oldenburg, MD, PhD, Department of Oncology, Akershus University Hospital (Ahus) and Professor, University of Oslo, Norway
4:00PM	Al and Surgery: Giovanni E. Cacciamani, MD, Associate Professor of Research, Urology & Radiology; Vice-Chair, Research Council; Director, Residents Research; and Director, Al Center @USC Urology, USC Institute of Urology, Catherine & Joseph Aresty Department of Urology, Keck School of Medicine, University of Southern California (USC), Los Angeles
4:10PM	Current Advances and Challenges in Data Integration and Standardization: Paul Boutros, PhD, MBA
4:20PM	Overview: Rakesh Shiradkar, PhD, Assistant Professor, Biomedical Engineering, Emory University. Member, Winship Cancer Institute
4:30PM- 5:30PM	Panel Discussion: Moderators, Speakers and Archan Khandekar, Instructor, Desai Sethi Urology Institute, Miller School of Medicine, University of Miami
8:00AM	WEDNESDAY, OCTOBER 9, 2024
	SESSION II (PART 1). CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
	Moderators:
	Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
	Baris Turkbey, MD, Senior Clinician, Molecular Imaging, Center for Cancer Research, National Cancer Institute, National Institutes of Health
8:10AM	Topic 1: Panel on Multiomics for Prostate Cancer
8:10AM	Topic 1A: Emerging Advances in Prostate Cancer Genomics and Proteomics - Year in Review: Paul Boutros, PhD, MBA
8:20AM	Q & A
8:22AM	Topic 1B: Molecular and Multi-Modality Imaging for Visualization and Staging of the Initial and Recurrent Disease
8:22AM	Advanced Ultrasound: Adam Kinnaird, MD, PhD, FRCSC, Frank and Carla Sojonky Chair in Prostate Cancer Research; Assistant Professor, Division of Urology, Department of Surgery; and Adjunct Assistant Professor, Department of Oncology, University of Alberta, Canada
8:32AM	Q & A
8:34AM	MRI: Baris Turkbey, MD, Radiologist, National Cancer Institute, National Institutes of Health
8:44AM	Q & A
8:46PM	Molecular Imaging: Stefano Fanti, MD, Professor, Department of Medical and Surgical Sciences, Head of Nuclear Medicine, University of Bologna, Italy
8:56AM	Q & A
8:58AM	Topic 1D: Integration of Imaging with Histology, Proteomics and Genomics - Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA

9:08AM-

9:30AM

Panel Discussion: Multiomics

9:30AM-10:00AM

COFFEE BREAK

10:00AM

SESSION II (PART 2): CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER

Moderators:

Carlos A. Buchpiguel, MD, PhD, Director of Molecular Imaging and Nuclear Medicine Division; and Full Professor, Department of Radiology and Oncology, São Paulo University School of Medicine, São Paulo -SP, Brazil

Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF (TBC)

Andrei H. Iagaru, MD, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging; and Co-Director, PET-MRI Research Program Stanford University

Raja B. Khauli, MD, Professor of Urology, American University of Beirut Medical Center, Beirut, Lebanon; and Professor of Surgery and Urology, Carle Health, College of Medicine, University of Illinois in Urbana-Champaign

Adam Kibel, MD, Chief of Urology, Brigham Health & Dana-Farber Cancer Institute, DiNovi Family Distinguished Chair in Urology, Brigham and Women's Hospital, Elliott Carr Cutler Professor of Surgery, Harvard Medical School (TBC)

Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute

10:00AM

Topic 2: Gleason Scoring Has Served Us Well for More than 50 Years, But It Is Time to Start Afresh: Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan Kettering Cancer Center (TBC)

10:10AM Q & A

10:12AM

Topic 3: Artificial Intelligence for Improving Prostate Cancer Diagnosis and Treatment: Wayne Brisbane, MD, Assistant Professor of Urology, UCLA

10:22AM Q & A

10:24AM

Topic 4: Construction and Multi-Center Validation of the Radiomics Model for Non-Invasive Identification of Active Surveillance Candidates: Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University, China

10:34AM Q & A

10:36AM-12:00PM Panel Discussion

12:00PM

Topic 5: Integration of Precision Diagnosis and Precision Treatment

12:00PM

Topic 5A: Integrated Diagnostics (Radiogenomics) and Patient Selection and Monitoring for Active Surveillance, Surgical and Radiation Treatment: Sanoj Punnen, MD, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research, Associate Professor and Vice Chair of Research, Department of Urology Co-Chair of Genitourinary Site Disease Group, Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine

12:10PM Q & A

12:12PM To

PM Topic 5B: Selection and Outcomes of Image-Guided, Minimally -Invasive Treatment: Abhinav Sidana, MD, MPH, Associate Professor of Surgery, Director of Urologic Oncology, University of Cincinnati College of Medicine (TBC)

12:22PM Q & A

12:24PM *Topic 5C: Radiation Treatment:* Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University (TBC)

12:34PM Q & A

12:36PM Panel Discussion: Integration of Precision Diagnosis and Treatment

1:00PM-**LUNCH BREAK** 2:30PM 2:30PM SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER **Moderators:** David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program Steven Finkelstein, MD, DABR, FACRO, Florida Cancer Affiliates, the US Oncology Network; and Board of Chancellors, American College of Radiation Oncology Fernando Maluf, MD, PhD, Director of Medical Oncology, Beneficencia Portuguesa; and Member, Steering Committee, Medical Oncology Center, Albert Einstein Hospital, São Paulo, Brazil (TBC) 2:30PM Topic 1: Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease 2:30PM Topic 1A: Review of the New Standard in Treatment for Oligometastatic Disease: Androgen Deprivation Treatment (ADT), Chemotherapy, Androgen Receptors Inhibitors, and Androgen Synthesis Inhibitors: Marc Garnick, MD, Director of Cancer Community Services, BIDMC; and Gorman Brothers Clinical Professor of Medicine at Harvard Medical School; and Special Advisor, Oncologic Drugs Advisory Committee of the FDA 2:40PM Q & A 2:42PM Topic 1B: Multi-Disciplinary Approach to Advanced Prostate Cancer Care: Kelvin A. Moses, MD, PhD, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel (TBC) 2:52PM Q & A 2:54PM Topic 1C: Radiation Treatment and Its Integration with Precision Diagnostics 2:54PM Radiation Therapy Planning Using Advanced Imaging - Pearls and Pitfalls: Sean P. Collins MD, PhD, Professor of Radiation Medicine and Director, CyberKnife Prostate Program, Department of Radiation Medicine, Medstar Georgetown University Hospital, Lombardi Comprehensive Cancer Center 3:04PM Topic 1D: Emerging Advances in Precision Radiation Treatment: Steven Finkelstein, MD, DABR, FACRO 3:14PM Q & A 3:16PM Topic 1E: Novel Targeted Treatment: Daniel P. Petrylak, MD. Professor of Medicine and Director of Genitourinary Oncology; and Co-Director of Signal Transduction Program, Yale University (TBC) 3:26PM Q & A 3:28PM Topic 1F: Precision Diagnostics and Emerging Treatment Strategies: David Nanus, MD 3:38PM Q & A 3:40PM Topic 1G: Immunotherapy: Sandy Srinivas, MD, Medical Oncologist, Stanford Health Care; Professor of Medicine (Oncology) and Urology, Stanford University; and Vice Chair, NCCN Panel for Prostate Cancer Treatment 3:50PM Q & A Topic 1H: Sequencing of Treatment: Arnulf Stenzl, MD, Professor and Chairman, Department of Urology, University 3:52PM of Tuebingen, Germany; Secretary General Adjunct - European Association of Urology; and Member, European Cancer Organization (ECO) Board of Directors 4:02PM Q & A

4:20PM 4:20PM-4:40PM

Panel Discussion: Standard and Emerging Treatment

4:04PM-

4:40PM Topic 2: Molecular and Multi-Modality Imaging and Theranostics Topic 2A: Molecular Imaging for Staging and Treatment Planning, including Patient Eligibility and Selection for 4:40PM LuPSMA Therapy: (Speaker to be announced) 4:50PM Q & A 4:52PM-Panel Discussion: Molecular Imaging and Theranostics: Speakers, Moderators and Brandon Mancini, MD, MBA, 6:00PM Medical Director, BAMF Health THURSDAY, OCTOBER 10, 2024 8:00AM SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, **Monitoring & Outcomes** Moderators: David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York Derek Lomas, MD, Assistant Professor of Urology, Mayo Clinic Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine Stephen Zappala, MD, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine (TBC) 8:10AM Topic 1: Changing Relationship between Active Surveillance and Focal Therapy: Mark Emberton, MD Q & A 8:20AM 8:22AM Topic 2: Patient Selection for Focal Therapy - Radiologic Perspective: Jurgen Futterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, 8:32AM RadboudUMC Nijmegen, The Netherlands; and Professor, Robotics and Mechanics Group, University of Twente, the Netherlands 8:42AM John Feller, MD, Chief Medical Officer, HALO Diagnostics; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine (TBC) 8:52AM Q & A 8:56AM Topic 3: Patient Selection for Prostate Cancer Focal Therapy – Urologic Perspective: Geoffrey Sonn, MD, Associate Professor of Urology and Radiology, Stanford University School of Medicine 9:06AM Q & A Topic 4: Panel on Addressing Fundamental Challenges in Clinical Acceptance and Adoption of Image-Guided 9:08AM Treatment- Perspective from the AdMeTech Foundation's International MRI Working Group 9:08AM Introduction: Faina Shtern, MD Standardized MRI and Molecular Imaging Reporting for Focal Therapy Follow-up - Creating Imaging-Based Short 9:18 AM and Intermediate Outcomes: Daniel Margolis, MD, Associate Professor of Radiology, Director, Prostate MRI, and Chair, Weill Cornell Institutional Review Board, Weill Cornell Medical College, Cornell University 9:28AM Q & A PI-FAB Standardization of MRI Reporting: Francesco Giganti, MD, PhD, Associate Professor of Radiology, Faculty of 9:30AM Medical Sciences, University College London, Honorary Consultant Radiologist, University College London Hospitals

Q & A

9:40AM

9:42AM	TARGET Consensus on Post-Treatment MRI Reporting: Taimur T. Shah, MBBS, BSc (Hons), FRCS (Urol), PhD, Clinical Senior Lecturer & Consultant Urologist, Prostate Cancer MDT Lead, Prostate Cancer UK (PCUK) Clinical Champion Imperial College London & Imperial College Healthcare NHS Trust
9:52AM	Q & A
9:54AM- 10:15AM	Panel on MRI Reporting Recommendations and Discussion: Led by Francesco Giganti, MD and Daniel Margolis, MD. Moderators, Speakers, and Angela Tong, MD, Clinical Assistant Professor, Abdominal Imaging Section, Departments of Radiology and Urology, NYU Langone Health
10:15AM- 11:15AM	Panel on Molecular Imaging Post Focal Treatment – Emerging Data and Next Steps: Led by Andrei lagaru, MD
10:15AM- 10:45AM	Emerging Data: Stefano Fanti, MD; Irene Burger, MD, Head of Nuclear Medicine, Kantonsspital Baden, Baden Switzerland; Attending Nuclear Medicine, University Hospital Zurich, Switzerland (TBC); Andrei lagaru, MD
10:45AM- 11:15AM	Panel on Molecular Imaging - Recommendations and Discussion: Led by Andrei lagaru, MD
11:15AM- 1:00PM	LUNCH BREAK
1:00PM	PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
	Moderators:
	Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine - Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
	Quoc-Dien Trinh, MD, MBA, Chief of Urology, Brigham and Women's Faulkner Hospital, Co-Director, Dana-Farber/Brigham and Women's Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School
1:00PM	Risk Assessment in Black Men: Adam B Murphy, MD, MBA, MSCI
1:10PM	Q & A
1:12PM	Utilization and Disparity Patterns Related to PC Markers: Michael Leapman, MD, MHS, Associate Professor of Urology, Clinical Program Leader, Prostate and Urologic Cancers Program, Yale Cancer Center
1:22PM	Q & A
1:24PM	Outreach Program to Address Racial Disparities in Prostate Cancer Care: Quoc-Dien Trinh, MD, MBA
1:34PM	Q & A
1:36PM- 2:00PM	Panel Discussion: Health Disparities
2:00PM- 2:40PM	COFFEE BREAK
2:40PM- 3:10PM	PRESENTATION OF WINNING ABSTRACTS

3:10PM-

4:00PM

4:00PM

GENERAL DISCUSSION

ADJOURN